Social News
Written by: Chen Shuxia
2021-05-09 19:45
Last update date: 2021-05-09 19:46
Fosun Pharma, which is responsible for introducing the BioNTech new crown vaccine produced by Germany to the Greater China region for sale, announced today (9th) that its holding subsidiary, Fosun Pharmaceutical Industry, intends to establish a joint venture company with BioNTech to realize the "local" of vaccine products. Chemical production and commercialization".
According to the information, the vaccines supplied by Fosun Pharma to Hong Kong will be directly produced by BioNTech's plant in Germany for the supply, distribution and administration of the Hong Kong Special Administrative Region Government’s new crown vaccination plan.
On February 27 this year, the first batch of BioNTech vaccines arrived in Hong Kong.
(Information Picture/Provided by Information Services Department)
In the evening, a mainland vaccine stock listed in Hong Kong, Fosun Pharma issued an announcement stating that its holding subsidiary Fosun Pharmaceutical Industry intends to invest in a joint venture with BioNTech to realize the "localized production and commercialization" of mRNA COVID-19 vaccine products.
According to the agreement, the two parties will respectively subscribe 50% of the registered capital of the joint venture company. Among them, Fosun Pharmaceutical Industry intends to use cash and/or tangible or intangible assets (including plant and production facilities, etc.) to contribute a total of not more than US$100 million. BioNTech intends Intangible assets such as related production technology and proprietary technology licenses shall not exceed 100 million U.S. dollars in total.
▼See the details of the scheduled vaccination and side effects of Kexing and BioNTech in the three pictures▼
The local Fubital vaccine is produced in Germany
According to the search data, Fosun Pharma is a strategic partner of BioNTech of Germany in China. The two parties will jointly develop and commercialize mRNA vaccine products based on BioNTech's proprietary mRNA technology research and development in China and Hong Kong, Macao and Taiwan.
According to the agreement, Fosun Pharmaceutical Industry is responsible for advancing the clinical trials, listing applications, and market sales of the product in China; BioNTech is responsible for providing technical materials and preclinical research materials required for clinical trial applications in the region, and cooperating with clinical trials in the region. And supply these products for clinical trials and market sales.
After Fosun Pharma was approved by Hong Kong for emergency use in January this year, it issued a press release stating that the vaccines supplied to Hong Kong will be directly produced by BioNTech’s plant in Germany for the supply, distribution and distribution of the vaccine under the Hong Kong Special Administrative Region Government’s new crown vaccination plan Application etc.
▼The last two days of foreign domestic helper testing on May 8▼
+8
+8
+8
New Crown Vaccine｜Pfizer and BioNTech apply for full approval in the United States
Fubitai｜BioNTech: After the third injection, the expert said that more data is needed to judge
Fubitai Vaccine | BioNTech expects to take the third shot within one year to improve the protection of the vaccine
New Crown Vaccine｜American Chamber of Commerce in Shanghai: BioNTech vaccine approved for use in the Mainland as soon as June
New crown vaccine | Pfizer BioNTech delivers EU vaccine early to make up for J&J’s shortage of supply
New crown vaccine|Israel research: South Africa variant virus can break through the BioNTech vaccine defense line
01News
New crown pneumonia new crown vaccine